AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Aug 2022 07:00 AM
RNS
Farxiga reduced risk of CV death or worsening HF
25 Aug 2022 07:10 AM
RNS
Ultomiris approved in Japan for gMG
25 Aug 2022 07:05 AM
RNS
Tagrisso approved in Japan for early lung cancer
25 Aug 2022 07:00 AM
RNS
Lynparza approved in Japan for early breast cancer
16 Aug 2022 07:00 AM
RNS
Lynparza granted FDA priority review for PROpel
15 Aug 2022 07:00 AM
RNS
Enhertu improved PFS in mBC in DESTINY-Breast02
12 Aug 2022 07:00 AM
RNS
Enhertu approved in US for HER2-mutant NSCLC
11 Aug 2022 07:00 AM
RNS
Acquisition of TeneoTwo completed
08 Aug 2022 07:10 AM
RNS
Enhertu approved in the US for HER2-low mBC
04 Aug 2022 07:00 AM
RNS
Lynparza approved in EU for early breast cancer
01 Aug 2022 05:00 PM
RNS
Director/PDMR Shareholding
01 Aug 2022 03:05 PM
RNS
Director/PDMR Shareholding
01 Aug 2022 03:00 PM
RNS
Total Voting Rights
29 Jul 2022 07:01 AM
RNS
Chair succession
29 Jul 2022 07:00 AM
RNS
Half-year Report
25 Jul 2022 07:10 AM
RNS
Tezspire recommended for EU approval in asthma
25 Jul 2022 07:05 AM
RNS
Ultomiris recommended for EU approval for gMG
25 Jul 2022 07:00 AM
RNS
Enhertu granted Priority Review for HER2-low mBC
19 Jul 2022 07:00 AM
RNS
Enhertu approved in EU for HER2-positive mBC
05 Jul 2022 07:00 AM
RNS
AstraZeneca to acquire TeneoTwo and T cell engager
01 Jul 2022 03:00 PM
RNS
Total Voting Rights
30 Jun 2022 07:00 AM
RNS
Imfinzi improved pCR in resectable lung cancer
27 Jun 2022 07:05 AM
RNS
Enhertu recommended for breast cancer EU approval
27 Jun 2022 07:00 AM
RNS
Lynparza recommended in EU for early breast cancer
21 Jun 2022 07:00 AM
RNS
Eplontersen Ph III trial met co-primary endpoints
06 Jun 2022 07:00 AM
RNS
Enhertu efficacy results in HER2-low breast cancer
01 Jun 2022 03:00 PM
RNS
Total Voting Rights
01 Jun 2022 03:00 PM
RNS
Block listing Interim Review
20 May 2022 04:00 PM
RNS
Director/PDMR Shareholding
09 May 2022 01:00 PM
RNS
Appointment of joint corporate brokers
06 May 2022 04:00 PM
RNS
Director/PDMR Shareholding
05 May 2022 07:10 AM
RNS
Enhertu approved in US for 2L HER2+ breast cancer
05 May 2022 07:05 AM
RNS
Farxiga HFpEF Phase III trial met primary endpoint
05 May 2022 07:00 AM
RNS
Ultomiris NMOSD Ph. III trial met primary endpoint
04 May 2022 07:00 AM
RNS
Imfinzi combo granted Priority Review for BTC
03 May 2022 03:00 PM
RNS
Total Voting Rights
29 Apr 2022 05:30 PM
RNS
Result of AGM
29 Apr 2022 07:05 AM
RNS
AstraZeneca plans new R&D centre in Massachusetts
29 Apr 2022 07:00 AM
RNS
First quarter 2022 results
28 Apr 2022 07:00 AM
RNS
Ultomiris approved in the US for adults with gMG
27 Apr 2022 07:00 AM
RNS
Enhertu granted BTD for HER2-low breast cancer
25 Apr 2022 07:00 AM
RNS
Tremelimumab US Priority Review for Imfinzi combo
19 Apr 2022 07:00 AM
RNS
Enhertu granted Priority Review for HER2m NSCLC
01 Apr 2022 03:00 PM
RNS
Total Voting Rights
29 Mar 2022 07:00 AM
RNS
Ondexxya approved in Japan for FXai reversal
28 Mar 2022 07:00 AM
RNS
Evusheld approved in the EU for COVID-19
25 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
24 Mar 2022 06:00 PM
RNS
Evusheld Positive EU CHMP Opinion
24 Mar 2022 07:00 AM
RNS
Update on CALLA Phase III trial for Imfinzi
23 Mar 2022 11:00 AM
RNS
Notice of AGM
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings